Company news: J&J's Janssen

Share this article:
An Arkansas judge levied a $1.2 billion fine on Johnson & Johnson's Janssen after a jury there found the pharma giant guilty of downplaying the risks of its antipsychotic Risperdal. The fine is far and away the largest in a statewide case, though judges and juries in South Carolina, Louisiana and Texas have ordered the firm to pay more than three-quarters of a billion dollars in Risperdal cases combined. J&J's Ortho-McNeil and Janssen units are operating under at federal Corporate Integrity Agreement related to Topamax marketing abuses.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.